Glioblastoma is universally fatal because of its propensity for rapid recurrence due to highly migratory tumor cells. Unraveling the genomic complexity that underlies this migratory characteristic could provide therapeutic targets that would greatly complement current surgical therapy. Using multiple high-resolution genomic screening methods, we identified a single locus, Adherens Junctional Associated Protein 1 (AJAP1) on chromosome 1p36, that is lost or epigenetically silenced in many glioblastomas. We found AJAP1 expression absent or reduced in 86% and 100% of primary glioblastoma tumors and cell lines, respectively, and the loss of expression correlates with AJAP1 methylation. Restoration of AJAP1 gene expression by transfection or demethylation agents results in decreased tumor cell migration in glioblastoma cell lines. This work demonstrates the significant loss of expression of AJAP1 in glioblastoma and provides evidence of its role in the highly migratory characteristic of these tumors.
Introduction
Glioblastoma is one of the most common and most malignant primary brain tumors in adults(1). Successful resection of >98% of the tumor alone only provides about 8 months of survival because tumor cells have invariably begun migrating away from the visible primary tumor focus. Adjuvant chemo-and radiotherapies provide some benefit. In a recent metaanalysis, an increase in median survival, from 12.1 to 14.6 months was observed in glioblastoma patients after multimodal therapy with gross total resection, radiotherapy, and chemotherapy with the alkylating drug temozolomide (2) .
In order to make significant strides in glioblastoma treatment, novel insights into the biology of these tumors are required. Recent genome-wide studies continue to elucidate the common genetic changes and altered signaling cascades in glioblastoma (3, 4) . These studies also highlight the large number of genetic changes due to the acquired mutator phenotype that may not play a central role in tumor initiation, proliferation, or cell migration (5) . Despite the plethora of genetic alterations seen in glioblastoma, most revealing genetic studies have typically implicated only a few altered signaling pathways, namely, activating events in the PTEN or receptor tyrosine kinase pathways and decreased activity in the RB1 or TP53 signaling cascades (3, 6) .
For many cancers the distal arm of chromosome 1p has been a mutational hotspot. A variety of human cancers, including glioblastoma, neuroblastoma, oligodendroglioma, leukemia, lymphoma, squamous cell carcinoma, breast cancer, and prostate cancer frequently have genetic deletions at 1p36. In glioblastoma, methylation appears to be a common event that also silences gene expression of tumor suppressor genes, including RB1, p16 INK4a , p14 ARF , MGMT, TIMP3 (7) , TMS1/ASC (8, 9) , CASP8 (10), RUNX3, and RES (11) . Unfortunately, the vast majority of these genetic and epigenetic events have yet to provide meaningful therapeutic or prognostic markers, except possibly for the case of MGMT (12) .
One unfortunate characteristic of glioblastoma is its robust propensity to migrate from the primary focus of tumor initiation to distant sites and to recur despite aggressive local and system therapies. Effective therapies that could impede this process of tumor cell migration could provide potentially curative adjunctive therapy to the current standard of care. Adherens Junctional Associated Protein-1 (AJAP1; also known as Shrew1) has recently been discovered as a novel transmembrane component of adherent junctions in epithelial cells (13) . Digital karyotyping. Digital karyotyping libraries were constructed as previously described (14) . Eighteen glioblastoma libraries (14 adult and 4 pediatric) were generated and the data combined with 9 glioblastoma libraries from TCGA database, for a total of 27 libraries.
Materials and Methods
Digital karyotyping protocols and software for extraction and analysis of genomic tags are available at http://www.digitalkaryotyping.org.
The Cancer Genome Atlas (TCGA). Using the TCGA Data Portal at http://tcgadata.nci.nih.gov/tcga/findArchives.htm we downloaded all copy number data generated at the Memorial Sloan Kettering Cancer Center. All normal blood, normal tissue, cell line, and duplicate data were removed yielding 221 glioblastoma primary tumors for analysis. TCGA raw data was reformatted for analysis by Nexus Copy Number Professional software (Biodiscovery, Inc, Segundo, CA).
Rembrandt. Data regarding expression, copy number, and survival obtained from http://tr.nci.nih.gov/rembrandt website, release date 11-13-09. This dataset included 506 samples for gene expression data, 722 for copy number data, and 891 for clinical data.
Illumina's HumanHap 550 Quad and 610 Duo Genotyping BeadChips. The Illumina
BeadChips enable whole-genome genotyping of over 555,000 and 610,000 tag SNP markers, respectively, derived from the International HapMap Project (www.hapmap.org). Thirty-five tumors were analyzed by the 550 chip, and another 43 tumors were analyzed by the 610 chip for a total of 78 unique samples. Blood and normal cortex were included. Genomic DNA was isolated with the QIAamp DNA Mini Kit (Qiagen, Valencia, CA), hybridized to the BeadChip microarrays, and data analyzed by using Illumina BeadStudio software. Illumina raw data was reformatted by Nexus.
Serial Analysis of Gene Expression (SAGE)
. SAGE data were reviewed on the NCBI Cancer Genome Anatomy Project repository (http://cgap.nci.nih.gov/SAGE). Additionally, we identified the SAGE sequence tags for the AJAP1 locus previously published [Supplemental Table S8 in (15) ].
RNA extraction, cDNA synthesis, quantitative PCR (Q-PCR).
Total RNA was isolated by using RNeasy Mini Kit (Qiagen) and reverse-transcribed by using an iScript™cDNA Synthesis Kit (Bio-Rad, Hercules, CA). cDNA amplification was monitored by using a SYBR Green protocol (Sigma, St. Louis, MO) on a 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA). Forward and reverse primers were designed at different exons.
GAPDH was used as control. Quantitative values were obtained from the threshold cycle (Ct) number at which the increase in the signal associated with exponential growth of PCR products could first be detected by using SDS2.2.2 software (Applied Biosystems). The transcript level of AJAP1 gene was normalized to that of GAPDH. As a reference, we used adult human brain RNA (BioChain Institute, Hayward, CA).
Bisulfite Treatment of DNA and Methylation-Specific quantitative PCR. Genomic DNA was isolated from fresh-frozen tissue samples and cell lines using Wizard® Genomic DNA Purification Kit (Promega, Madison, WI). Using Methprimer (http://urogene.org/methprimer), we performed a CpG island search throughout intragenic and promoter regions up to 3000 bp upstream of the start site for AJAP1. Bisulfite modification of genomic DNA was performed using EZ DNA Methylation-Gold Kit™ (Zymo, Orange, CA). Methylation-specific qPCR was carried out with 2 µl of bisulfite-treated DNA using a SYBR Green PCR Kit (Qiagen) on an ABI PRISM 7900 HT system (Applied Biosystems) according to the manufacturer's instructions.
Two sets of methylation-specific and two sets of unmethylation specific primers were used. The FBS. Cells that migrated to the underside of the chamber were fixed with 3.7% paraformaldehyde, stained with 0.5% crystal violent, and the membranes were dissolved with 33% acetic acid. Cells were photographed and hand-counted by light microscopy, as well as optically densitized at 595nm by an ELISA plate reader.
Statistical analysis.
All experiments were done in triplicate. Statistical significance was set a priori at P<0.05. Analyses were performed with Microsoft Excel and SAS E-guide statistical packages (SAS, Inc., Cary, NC).
Results

AJAP1 is deleted in glioblastoma.
We used different methods to perform genome-wide screens in glioblastoma samples for genetic alterations. We initially used digital karyotyping, which can be reliably used to identify chromosomal changes, amplifications, deletions, and the presence of foreign DNA sequences (14, 16) . We evaluated 27 glioblastoma libraries with an Table T1 ). In summary, our analysis of this hotspot for genetic alterations on chromosome 1p36 in 105 samples using independent sets of genomic data reveals the unique deletion of AJAP1 in up to 16% of glioblastoma tumors. AJAP1 expression is downregulated in glioblastoma tumors and cell lines. We initially examined AJAP1 expression in 13 primary glioblastoma samples, 8 glioma cell lines and 4 normal brain samples by using Q-PCR. We found that AJAP1 expression was markedly reduced or absent in 92% (12/13) primary glioblastomas (Fig. 3A, TB samples) and all glioblastoma cell lines tested (Fig. 3A, D and U samples) . We expanded this study to our entire original set of 80 primary tumors and found reduced or absent expression in 86% (Supplementary Data Table T1 ). We also performed a search of a public cancer genome SAGE database (http://cgap.nci.nih.gov/SAGE) and confirmed that AJAP1 expression is significantly reduced in glioblastoma, with an average of three AJAP1 SAGE tags in glioblastoma compared with 12 tags in normal human brain. Finally, we explored the sequence tag density for AJAP1 in another SAGE database previously published [see Supplementary Table S8 in (15)]. In this database of 16 glioblastoma tumors, 14 tumors (88%) had sequence tag densities markedly reduced when compared to a normal sample (Fig. 3B) . (Fig. 4A) . Using quantitative methylation-sensitive PCR on bisulfite treated samples, we found that the AJAP1 promoter was often methylated in glioblastoma primary tumors and glioma cell lines (Fig. 4B-C) . We initially observed significant AJAP1 promoter methylation in 13 of 20 primary glioblastoma (65%) and 9 of 10 cell lines (90%) (Fig. 4B) . Normal brain samples were found to be unmethylated (Fig. 4B) . Glioblastoma cell lines U87MG and D54MG demonstrated the lowest levels of gene expression (Fig. 3A) and the highest number of CpG islands to be methylated (Fig. 4B) . We then examined our entire set of 80 primary tumors and found significant methylation (i.e. >10% of CpG islands tested) in 63% (Supplementary Data Table T1) Loss of AJAP1 expression is associated with increased glioma cell proliferation and migration. Prior studies suggest a potential role for AJAP1 in cell-cell and cell-extracellular matrix interactions that could be involved in cell motility, migration, and invasion (13, (17) (18) (19) .
These studies indicated that the effect of AJAP1 on tumor cell migration may depend upon the 
specific tumor type and its environment. Based on these findings and our evidence of loss of expression in glioblastoma, we hypothesize that AJAP1 may contribute to glioblastoma cell migration. We chose D409MG, a glioblastoma cell line with very low AJAP1 expression (Fig.   3A) and evidence of promoter methylation (Fig. 4B) . Overexpression of AJAP1 in D409MG with the pEGFP-AJAP1 expression resulted in a marked decrease in cell proliferation (Fig. 5A) and migration through Transwell migration assays (Fig. 5B) as compared to the same cell type transfected with the empty vector pEGFP-N1 (Fig. 5B) . We demonstrate similar findings in another glioma cell line as well (Supplementary Figure S5) .
Demethylation restores AJAP1 expression and function. Since AJAP1 can be epigenetically silenced in glioblastoma primary tumors and cell lines, pharmacologic reversal of this epigenetic silencing may be a viable option for restoring normal expression and function. To test this hypothesis, we selected the glioblastoma cell lines D54MG and U87MG, which demonstrate very low AJAP1 expression (Fig. 3A) and extensive promoter methylation (Fig.   4B ). Both cell lines were exposed to the methyltransferase inhibitor AZA and the histone deacetylase inhibitor TSA. AZA and TSA have been extensively used in preclinical and clinical studies for demethylating genes (20) . In D54MG and U87MG, AJAP1 expression is undetectable without exposure to either agent (Fig. 6A, lanes 1; Supplementary Data Figure S2 ), but expression is dramatically increased upon exposure to AZA (Fig. 6A, lanes 2 ; Supplementary   Data Figure S2 ) or TSA (Fig. 6A, lanes 3; Supplementary Data Figure S2 ). Densitometric quantification of the PCR products show that AJAP1 expression in both cells increased more than 50-fold (Fig. 6B) . Bisulfite sequencing confirms that these reagents dramatically reduce the number of methylated CpG islands in the AJAP1 promoter (Fig. 6C decrease in migration after treatment (Fig. 6D, hatched bar) . Furthermore, we are able to partially 'rescue' this phenotype and increase migration by knocking down the AJAP1 gene with siRNA after demethylation treatment (Fig. 6D, gray and diamond bars) . These results confirm that AJAP1 expression is epigenetically silenced in glioma cells, promoter methylation can be reversed pharmacologically, and restoration of AJAP1 expression by demethylation treatment decreases glioma cell migration.
Discussion
With high-resolution genome-wide mapping, we demonstrated in this study the deletion of AJAP1 in many glioblastoma cell lines and primary tumors (Figs. 1-2) . In a total of 105 samples, we discovered that up to16% have AJAP1 deleted; however, a much larger percentage deleted in 25% of neuroblastomas, an extracranial tumor of the sympathetic nervous system commonly seen in children (23) . AJAP1 was 1 of 6 predicted genes in this deleted region.
CHD5 was recently found to be a strong tumor suppressor gene candidate deleted from 1p36.31 in neuroblastomas and inactivation of the second allele was speculated to occur by an epigenetic mechanism (24) . This was discovered while mapping the smallest region of a consistently deleted segment at 1p36.31 that contained 23 genes, including AJAP1 (24). Milde et al recently showed the loss of AJAP1 in a progressively metastasizing ependymoma (25) .
In polarized epithelial cells, AJAP1 is a transmembrane protein that interacts with Ecadherin-β-catenin complexes (13), the adaptor protein complex AP-1B (17), and CD147 (26) . We have reviewed our available clinical data for the tumors tested in this manuscript and do not see a significant difference in AJAP1 deletion, expression, or methylation between primary and secondary glioblastoma.
There is an extensive array of other factors implicated in glioma cell migration where the potential relationship to AJAP1 expression is unexplored (4, 27) . During invasive migration, cancer cells use secreted, surface-localized and intracellular matrix metalloproteinases, serine proteases, and cathepsins to proteolytically clear and remove different types of extracellular matrix substrates at their interface, including collagens, laminins, vitronectin, and fibronection.
Some of these processes may be relevant to glioma cell migration as well. The role of these processes in glioblastoma migration and interaction with AJAP1 remains for further investigation.
Epigenetic silencing via cytosine methylation is a well-established and extensively used mechanism for gene regulation in numerous cancers, including glioblastoma. Genome-wide screens of glioma cells treated with AZA and TSA reveal >160 genes up-regulated by these treatments (28) . Using mutational and methylation analyses, we showed that AJAP1 expression is not due to mutation, but is epigenetically silenced with promoter methylation in many cases.
In our large series of primary tumors and cell lines, we see widespread evidence of AJAP1 methylation (Fig 4B) . Furthermore, this mechanism of gene silencing is effectively reversed with the common demethylating agents AZA and TSA (Fig. 6) . Restoration of AJAP1 expression by these pharmacologic agents returned its function by reducing tumor cell migration (Fig. 6D) .
We show that demethylation agents can target AJAP1 (Fig. 6D) ; however, since we are able to only partially recover migration by knocking down AJAP1 after demethylation treatment, we hypothesize that AZA/TSA treatment likely alters expression of other unknown genes that effect 
migration. Importantly, not all samples with low or no expression of AJAP1 demonstrate evidence of promoter methylation. Clearly, our data supports the observation that other mechanisms other than DNA methylation and gene mutation also play a role in AJAP1 expression. Targeting methylated genes in glioblastoma may be a viable option since demethylating agents have shown efficacy in preclinical and clinical trials (20, 29) .
Though all the methylated glioblastoma tumors showed reduced or silenced expression of AJAP1, one primary tumor (TB2479) and one cell line (D336MG) exhibited reduced AJAP1 expression in the absence of methylation in the analyzed region. It is likely that transcriptional activation of AJAP1 may also be influenced by other mechanisms, such as accessibility of AJAP1 regulator proteins or specific transcription factors.
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